$NXTC
NextCure Inc

2024 Q2 Form 10-Q Financial Statement

#000155837024006551 Filed on May 02, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.076M $4.364M
YoY Change -28.63% -19.54%
% of Gross Profit
Research & Development $12.42M $11.40M
YoY Change -7.65% -2.14%
% of Gross Profit
Depreciation & Amortization $701.0K $790.0K
YoY Change -26.52% -17.71%
% of Gross Profit
Operating Expenses $16.49M $18.30M
YoY Change -13.91% 7.22%
Operating Profit -$16.49M -$18.30M
YoY Change -13.91% 7.22%
Interest Expense $1.197M
YoY Change 22.77%
% of Operating Profit
Other Income/Expense, Net $1.090M $1.197M
YoY Change -16.09% 22.77%
Pretax Income -$15.40M -$17.11M
YoY Change -13.75% 6.28%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$15.40M -$17.11M
YoY Change -13.75% 6.28%
Net Earnings / Revenue
Basic Earnings Per Share -$0.55 -$0.61
Diluted Earnings Per Share -$0.55 -$0.61
COMMON SHARES
Basic Shares Outstanding 27.97M 27.90M
Diluted Shares Outstanding 27.97M 27.90M

Balance Sheet

Concept 2024 Q2 2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $86.44M $96.00M
YoY Change -33.83% -34.02%
Cash & Equivalents $20.85M $18.36M
Short-Term Investments $65.59M $77.64M
Other Short-Term Assets $4.019M $6.551M
YoY Change -14.05% 91.27%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $90.46M $102.6M
YoY Change -33.14% -31.14%
LONG-TERM ASSETS
Property, Plant & Equipment $6.699M $7.097M
YoY Change -55.99% -36.55%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.874M $1.878M
YoY Change -34.43% -33.48%
Total Long-Term Assets $12.13M $12.61M
YoY Change -32.89% -33.2%
TOTAL ASSETS
Total Short-Term Assets $90.46M $102.6M
Total Long-Term Assets $12.13M $12.61M
Total Assets $102.6M $115.2M
YoY Change -33.11% -31.37%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.075M $4.491M
YoY Change 80.41% 134.03%
Accrued Expenses $5.758M $5.092M
YoY Change 15.0% 17.14%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $10.83M $9.583M
YoY Change 38.53% 52.94%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $725.0K $755.0K
YoY Change -89.83% -13.42%
Total Long-Term Liabilities $725.0K $755.0K
YoY Change -89.83% -13.42%
TOTAL LIABILITIES
Total Short-Term Liabilities $10.83M $9.583M
Total Long-Term Liabilities $725.0K $755.0K
Total Liabilities $17.15M $16.11M
YoY Change 14.7% 18.57%
SHAREHOLDERS EQUITY
Retained Earnings -$357.0M -$341.6M
YoY Change 20.72% 22.94%
Common Stock $28.00K $28.00K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $85.44M $99.05M
YoY Change
Total Liabilities & Shareholders Equity $102.6M $115.2M
YoY Change -33.11% -31.37%

Cashflow Statement

Concept 2024 Q2 2024 Q1
OPERATING ACTIVITIES
Net Income -$15.40M -$17.11M
YoY Change -13.75% 6.28%
Depreciation, Depletion And Amortization $701.0K $790.0K
YoY Change -26.52% -17.71%
Cash From Operating Activities -$9.776M -$12.61M
YoY Change -33.71% -14.7%
INVESTING ACTIVITIES
Capital Expenditures $301.0K $37.00K
YoY Change 7.5% -85.08%
Acquisitions
YoY Change
Other Investing Activities $12.46M $17.92M
YoY Change 78.27% -2.46%
Cash From Investing Activities $12.16M $17.88M
YoY Change 81.22% -1.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 106.0K 1.000K
YoY Change 27.71%
NET CHANGE
Cash From Operating Activities -9.776M -12.61M
Cash From Investing Activities 12.16M 17.88M
Cash From Financing Activities 106.0K 1.000K
Net Change In Cash 2.490M 5.276M
YoY Change -131.31% 57.82%
FREE CASH FLOW
Cash From Operating Activities -$9.776M -$12.61M
Capital Expenditures $301.0K $37.00K
Free Cash Flow -$10.08M -$12.64M
YoY Change -32.94% -15.86%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.61
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.58
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
27903040
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
27774536
CY2024Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001661059
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27903027
CY2024Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27903627
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
27903040
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
27774536
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.61
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.58
CY2024Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2024Q1 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Current Statement Of Financial Position Extensible List
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#PrepaidExpenseAndOtherAssetsCurrent
CY2023Q4 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Current Statement Of Financial Position Extensible List
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#PrepaidExpenseAndOtherAssetsCurrent
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
001-38905
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
NextCure, Inc.
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-5231247
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
9000 Virginia Manor Road
CY2024Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 200
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Beltsville
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MD
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
20705
CY2024Q1 dei City Area Code
CityAreaCode
240
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
399-4900
CY2024Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
CY2024Q1 dei Trading Symbol
TradingSymbol
NXTC
CY2024Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2024Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
27973289
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18358000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13082000
CY2024Q1 us-gaap Debt Securities Available For Sale Excluding Accrued Interest Current
DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
77643000
CY2023Q4 us-gaap Debt Securities Available For Sale Excluding Accrued Interest Current
DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
95217000
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6551000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4426000
CY2024Q1 us-gaap Assets Current
AssetsCurrent
102552000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
112725000
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7097000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9033000
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3632000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4398000
CY2024Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1878000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1882000
CY2024Q1 us-gaap Assets
Assets
115159000
CY2023Q4 us-gaap Assets
Assets
128038000
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
4491000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2330000
CY2024Q1 nxtc Accrued And Other Liabilities Current
AccruedAndOtherLiabilitiesCurrent
5092000
CY2023Q4 nxtc Accrued And Other Liabilities Current
AccruedAndOtherLiabilitiesCurrent
4553000
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
9583000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6883000
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5773000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5949000
CY2024Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
755000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
785000
CY2024Q1 us-gaap Liabilities
Liabilities
16111000
CY2023Q4 us-gaap Liabilities
Liabilities
13617000
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27903627
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27903027
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
28000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
28000
CY2024Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
440791000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
439097000
CY2024Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-182000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-222000
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-341589000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-324482000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
99048000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
114421000
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
115159000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
128038000
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11398000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11647000
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4364000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5424000
CY2024Q1 us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
2542000
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
18304000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
17071000
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-18304000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-17071000
CY2024Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1197000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
975000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-17107000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-16096000
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.61
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.58
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27903040
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27774536
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-17107000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-16096000
CY2024Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
40000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
691000
CY2024Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-17067000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-15405000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
114421000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1693000
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000
CY2024Q1 nxtc Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax Adjusted
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTaxAdjusted
40000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-17107000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
99048000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
167530000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2078000
CY2023Q1 nxtc Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax Adjusted
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTaxAdjusted
691000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-16096000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
154203000
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-17107000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-16096000
CY2024Q1 nxtc Depreciation Depletion And Amortization And Other
DepreciationDepletionAndAmortizationAndOther
790000
CY2023Q1 nxtc Depreciation Depletion And Amortization And Other
DepreciationDepletionAndAmortizationAndOther
960000
CY2024Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
304000
CY2023Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-82000
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1693000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2078000
CY2024Q1 us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
1787000
CY2024Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-150000
CY2023Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-150000
CY2024Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2109000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1089000
CY2024Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2161000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2351000
CY2024Q1 nxtc Increase Decrease In Accrued And Other Current Liabilities
IncreaseDecreaseInAccruedAndOtherCurrentLiabilities
-539000
CY2023Q1 nxtc Increase Decrease In Accrued And Other Current Liabilities
IncreaseDecreaseInAccruedAndOtherCurrentLiabilities
551000
CY2024Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-176000
CY2023Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-113000
CY2024Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-30000
CY2023Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-27000
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12606000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14779000
CY2024Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
29055000
CY2023Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
49773000
CY2024Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
11137000
CY2023Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
31403000
CY2024Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
37000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
248000
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
17881000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
18122000
CY2024Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1000
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
5276000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
3343000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13082000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
26630000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18358000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
29973000
CY2024Q1 us-gaap Interest Paid Net
InterestPaidNet
19000
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
21000
CY2024Q1 nxtc Cash And Cash Equivalents And Marketable Securities At Carrying Value
CashAndCashEquivalentsAndMarketableSecuritiesAtCarryingValue
96000000.0
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of assets and liabilities as of the date of the condensed financial statements, and the reported amounts of revenues and expenses during the reporting periods. Although actual results could differ from those estimates, management does not believe that such differences would be material.</p>
CY2024Q1 us-gaap Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest Before Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss
77825000
CY2024Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
182000
CY2024Q1 us-gaap Debt Securities Available For Sale Excluding Accrued Interest
DebtSecuritiesAvailableForSaleExcludingAccruedInterest
77643000
CY2023Q4 us-gaap Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest Before Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss
95439000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
41000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
263000
CY2023Q4 us-gaap Debt Securities Available For Sale Excluding Accrued Interest
DebtSecuritiesAvailableForSaleExcludingAccruedInterest
95217000
CY2024Q1 us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
0
CY2023Q1 us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
0
CY2024Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
77600000
CY2024Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
7000000.0
CY2024Q1 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
74885000
CY2024Q1 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
74703000
CY2024Q1 nxtc Available For Sale Securities Debt Maturities After One Through Two Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsAmortizedCost
2940000
CY2024Q1 nxtc Available For Sale Securities Debt Maturities After One Through Two Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue
2940000
CY2024Q1 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
77825000
CY2024Q1 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
77643000
CY2024Q1 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss
600000
CY2023Q4 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss
800000
CY2024Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2024Q1 us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2024Q1 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2023Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
272000
CY2024Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
272000
CY2024Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
277000
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
246000
CY2024Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y
CY2024Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0746
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
850000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1214000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1355000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1396000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1438000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
1857000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
8110000
CY2024Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1659000
CY2024Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
6451000
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1693000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2078000
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.833
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.814
CY2024Q1 us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
1800000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-17107000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-16096000
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27903040
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27774536
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.61
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.58
CY2024Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9206104
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7030160
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2024Q1 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false

Files In Submission

Name View Source Status
0001558370-24-006551-index-headers.html Edgar Link pending
0001558370-24-006551-index.html Edgar Link pending
0001558370-24-006551.txt Edgar Link pending
0001558370-24-006551-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
nxtc-20240331.xsd Edgar Link pending
nxtc-20240331x10q.htm Edgar Link pending
nxtc-20240331xex31d1.htm Edgar Link pending
nxtc-20240331xex31d2.htm Edgar Link pending
nxtc-20240331xex32d1.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
nxtc-20240331_cal.xml Edgar Link unprocessable
nxtc-20240331_def.xml Edgar Link unprocessable
nxtc-20240331_lab.xml Edgar Link unprocessable
nxtc-20240331_pre.xml Edgar Link unprocessable
nxtc-20240331x10q_htm.xml Edgar Link completed
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending